Claims
- 1. A method for treating an individual with diabetes mellitus comprising administering to said individual an effective amount of fructosamine oxidase inhibitor to inhibit fructosamine oxidase activity associated with the diabetic state.
- 2. The method according to claim 1 wherein macrovascular and microvascular damage is lessened.
- 3. The method according to claim 2 wherein said damage is a cardiac-associated condition.
- 4. The method according to claim 3 wherein said condition is accelerated atherosclerosis.
- 5. The method according to claim 3 wherein said condition is diabetic cardiomyopathy.
- 6. The method according to claim 2 wherein said damage is blindness.
- 7. The method according to claim 2 wherein said damage is renal failure.
- 8. The method according to claim 2 wherein said damage is neuropathy.
- 9. The method according to claim 2 wherein said damage is diabetic cataract.
- 10. The method according to claim 1 wherein said inhibition occurs as a result of administration of at least one fructosamine oxidase inhibitor to said individual.
- 11. The method according to claim 10 wherein said inhibitor is a hydrazine compound carbidopa.
- 12. The method according to claim 11 wherein said hydrazine compound is administered to said mammal orally and wherein said amount is administered at a level which is not toxic to said individual.
- 13. The method according to claim 10 wherein said inhibitor is a substrate analog selected from the group consisting of Nα-CBZ-L-arginine and acetylpenicillamine.
- 14. The method according to claim 13 wherein said substrate analog is administered to said mammal orally and wherein said amount is administered at a level which is not toxic to said individual.
- 15. The method according to claim 10 wherein said inhibitor is a copper chelator and wherein said copper chelator is triene.
- 16. The method according to claim 15 wherein said copper chelator is administered to said mammal orally and wherein said amount is administered at a level which is not toxic to said individual.
- 17. A method of treating an individual with diabetes mellitus comprising administering an effective amount of copper chelator.
- 18. The method according to claim 17 wherein said copper chelator is triene.
- 19. The method according to claim 18 wherein said amount is administered at a level that is not toxic to said individual.
- 20. The method according to claim 19 wherein macrovascular and microvascular damage is lessened.
- 21. The method according to claim 20 wherein the amount administered to said individual decreases the amount of copper in the body.
- 22. The method according to claim 17 wherein the said amount affects copper metabolism as a result of administration of at least one copper chelator to said individual.
- 23. A method for treating an individual with diabetes mellitus comprising administering to said individual an effective amount of a combination of fructosamine oxidase inhibitors to inhibit fructosamine oxidase activity associated with the diabetic state.
- 24. The method according to claim 23 wherein said combination comprises a copper chelator and captropril.
- 25. The method according to claim 24 wherein said copper chelator is triene.
- 26. The method according to claim 25 wherein macrovascular and microvascular damage is lessened.
- 27. The method according to claim 23 wherein said combination comprises a copper chelator and carbidopa.
- 28. The method according to claim 27 wherein said copper chelator is triene.
- 29. The method according to claim 28 wherein macrovascular and microvascular damage is lessened.
- 30. The method according to claim 23 wherein said combination comprises acetylcysteine and carbidopa.
- 31. The method according to claim 30 wherein macrovascular and microvascular damage is lessened.
- 32. The method according to claim 23 wherein said combination comprises acetylcysteine and hydralazine.
- 33. The method according to claim 32 wherein macrovascular and microvascular damage is lessened.
- 34. The method according to claim 23 wherein said combination comprises acetylcysteine and a hydrazine compound.
- 35. The method according to claim 34 wherein macrovascular and microvascular damage is lessened.
Priority Claims (5)
Number |
Date |
Country |
Kind |
PCT/NZ99/00161 |
Sep 1999 |
NZ |
|
NZ337042 |
Aug 1999 |
NZ |
|
NZ334471 |
Mar 1999 |
NZ |
|
NZ332079 |
Sep 1998 |
NZ |
|
NZ332084 |
Sep 1998 |
NZ |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to PCT/NZ99/00161 filed on Sep. 24, 1999; New Zealand application 337042 filed on Aug. 9, 1999; New Zealand application 334471 filed on Mar. 3, 1999; New Zealand application 332079 filed on Sep. 28, 1998; and New Zealand application 332084 filed on Sep. 25, 1998, all of which are hereby incorporated by reference in their entirety.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09671967 |
Sep 2000 |
US |
Child |
09975751 |
Oct 2001 |
US |